{"prompt": "['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', 'a tumor-localized photosensitizer, has proven to be an effective local treatment for a range of solid', 'tumors. It has the potential to become an effective first line treatment modality for this disease for', 'the following reasons: it is minimally invasive, has low toxicity, is not associated with any long-', 'term morbidity and is repeatable. Importantly, it allows the physician to reserve conventional,', 'more toxic treatments such as radiotherapy and chemotherapy for later application, if needed.', 'The purpose of this multicenter study is to test the non-inferiority of PDT with HPPH to standard', 'of care by comparing the rate of tumor response and QoL after PDT to those obtained after surgery', 'in participants with previously untreated T1/T2 NO SCC of the oral cavity.', 'Phase I studies have demonstrated that this treatment is safe. These studies also determined the', 'safe drug and light dosages: 4 mg/m\u00b2 and 100 - 140 J/cm\u00b2, respectively. Data also suggest that', 'early stage SCC may have excellent response to this therapy (see Table 1).', 'In our recent study with HPPH-PDT, all the patients with T1/T2 who failed to have CR to PDT', 'were successfully salvaged with surgery. 18 Importantly, in patients with invasive disease who', 'achieved only PR, the disease could be downgraded to dysplasia, thus minimizing salvage surgery.', 'While all studies with HPPH-PDT to date have been Phase I studies, the response to PDT is swift', 'and all patients, with few exceptions, have been assessed for response by pathological analysis.', 'We believe that PDT with HPPH is a viable option to treat patients with T1/T2, because:', 'HPPH-PDT is expected to be an organ sparing treatment option, and failures can be', 'salvaged with surgery.', 'HPPH, at clinically effective antitumor doses, is associated with significantly reduced', 'cutaneous photosensitivity that rapidly declines over several days.41', 'The CR to HPPH-PDT is expected to be 85%, which would be comparable to cure rates', 'after the initial surgery that is associated with 20% local recurrence. 7-9', 'Noninvasive optical spectroscopy has potential to serve as a surrogate reporter for tumor', 'response to HPPH-PDT.48', 'Therefore, we hypothesize that patients may choose a treatment option, such as PDT with HPPH,', 'if it provides non-inferior cure rate at the time of the initial treatment.', '2.1', 'RATIONALE FOR ANCILLARY LABORATORY STUDIES', 'In the current study, immune cells will be collected from participants before and after PDT and', \"tested for reactivity to the participant's tumor cells. These will only be collected from participants\", 'randomized to PDT with HPPH. Refer to Appendix G.', '3', 'OBJECTIVES', '3.1', 'PRIMARY OBJECTIVE', 'To test the non-inferiority of PDT to standard of care surgery by comparing the rate of tumor', 'response after PDT to those observed after surgery, at 24 months post treatment.', '3.2', 'SECONDARY OBJECTIVES', 'To determine quality of life (QoL) at 6, 12, 18, and 24 months post PDT or surgery.', 'To assess the toxicity using the CTEP NCI Common Terminology Criteria for Adverse', 'Events (CTCAE Version 4.0).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 17 of 64']['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', '3.3', 'TERTIARY OBJECTIVE', 'Immune markers (T cells).', 'To investigate the correlation of the diffuse reflectance optical spectroscopy with tumor', 'response to PDT (Appendix B).', '4', 'METHODOLOGY', '4.1 STUDY DESIGN', 'This is an open-label, randomized, multicenter Phase II study of HPPH-mediated PDT in', 'participants with lesions that are diagnosed as previously untreated T1 NO or T2 NO SCC of the', 'oral cavity. Participants will be randomized at a ratio of 1:1, to be treated with either surgery (57', 'participants) or PDT with HPPH (57 participants). The randomization will be done at RPCI by the', 'biostatistician. The study schema is depicted in Figure 1.', 'Participants will be treated on an outpatient basis. Rarely, those undergoing HPPH with PDT may', 'require hospitalization but this will be decided on a case by case basis. Participants undergoing', 'surgery may be hospitalized.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 18 of 64']\n\n###\n\n", "completion": "END"}